Related references
Note: Only part of the references are listed.Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with Clopidogrel in acute coronary syndrome
Corinne Frere et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
Matthew J. Price et al.
EUROPEAN HEART JOURNAL (2008)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice -: 4-year results from a large 2-institutional cohort study
Peter Wenaweser et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Pharmacokinetics of clopidogrel in patients with stent thrombosis
D. Sibbing et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
K. Umemura et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Cytochrome P4502C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
Betti Giusti et al.
PHARMACOGENETICS AND GENOMICS (2007)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Outcomes associated with drug-eluting and bare-metal stents:: a collaborative network meta-analysis
Christoph Stettler et al.
LANCET (2007)
Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
L. Bonello et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
Piergiovanni Buonamici et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Clinical end points in coronary stent trials - A case for standardized definitions
Donald E. Cutlip et al.
CIRCULATION (2007)
Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel
Dominick J. Angiolillo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment -: The ISAR-REACT 2 randomized trial
A Kastrati et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
SC Smith et al.
CIRCULATION (2006)
Stent thrombosis is associated with an impaired response to antiplatelet therapy
P Wenaweser et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation
ATL Ong et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Variability in platelet responsiveness to clopidogrel among 544 individuals
VL Serebruany et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
WC Lau et al.
CIRCULATION (2004)
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel
A Kastrati et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel
J Mehilli et al.
CIRCULATION (2004)
A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries
J Hausleiter et al.
JOURNAL OF INTERNAL MEDICINE (2004)
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
JA Goldstein
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
FJ Neumann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
Identification of the platelet ADP receptor targeted by antithrombotic drugs
G Hollopeter et al.
NATURE (2001)
Share Paper
